Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

  • Abiraterone Improves Survival in Metastatic Prostate Cancer
    (Posted: 07/27/2011, Updated: 12/31/2012) - A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.
  • New Drug Shows Promise against Drug-Resistant Leukemias
    (Posted: 12/17/2012) - A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.
  • New Targeted Treatment May Slow Disease in Patients with Advanced GIST
    (Posted: 12/11/2012) - A new oral drug, regorafenib (Stivarga®), may delay the progression of advanced gastrointestinal stromal tumors (GIST) that are resistant to treatment, according to results from an international clinical trial published November 22, 2012, in The Lancet.
  • Adding Chemotherapy to Radiation Improves Survival for Some Patients with Rare Brain Cancer
    (Posted: 11/29/2012) - Long-term results from two clinical trials confirm that certain patients with rare brain tumors called anaplastic oligodendrogliomas live substantially longer if they are treated with a combination of chemotherapy and radiation therapy rather than radiation alone.
  • For Some Breast Cancers, New Drug May Be Treatment Option
    (Posted: 06/13/2012, Updated: 11/29/2012) - Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option. Women who received the investigational drug trastuzumab emtansine (T-DM1) lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine (Xeloda) and the targeted drug lapatinib (Tykerb).
< Previous  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  Next >